Cargando…

Thromboembolic risk with IVIg: Incidence and risk factors in patients with inflammatory neuropathy

Our objective was to evaluate whether IV immunoglobulin (IVIg) increases the risk of thromboembolic events in neurology outpatients with inflammatory neuropathies, as there is conflicting evidence supporting this hypothesis, mainly from non-neurologic cohorts. We investigated this question over 30 m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapoor, Mahima, Spillane, Jennifer, Englezou, Christina, Sarri-Gonzalez, Scherezade, Bell, Robert, Rossor, Alexander, Manji, Hadi, Reilly, Mary M., Lunn, Michael P., Carr, Aisling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136065/ https://www.ncbi.nlm.nih.gov/pubmed/31852814 http://dx.doi.org/10.1212/WNL.0000000000008742

Ejemplares similares

Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kapoor, Mahima, et al.
Publicado: (2022)

Pilot phenotype and natural history study of hereditary neuropathies caused by mutations in the HSPB1 gene
por: Rossor, Alexander M., et al.
Publicado: (2017)

Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg
por: Turner, Lindsey E., et al.
Publicado: (2019)

Blood biomarkers of peripheral neuropathy
por: Rossor, Alexander M., et al.
Publicado: (2022)

Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis
por: Kapoor, Mahima, et al.
Publicado: (2019)

Review process for IVIg treatment: Lessons learned from INSIGHTS neuropathy study
por: Levine, Todd D., et al.
Publicado: (2018)

Thromboembolic complications of intravenous immunoglobulin (IVIG) in an immunocompromised patient with Chronic Lymphocytic Leukemia: a case report
por: Milani, Cannon, et al.
Publicado: (2009)

Treatment of scleromyxedema with IVIg
por: Moser, David W, et al.
Publicado: (2012)

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
por: Wang, Zhouping, et al.
Publicado: (2020)

RFC1 expansions are a common cause of idiopathic sensory neuropathy
por: Currò, Riccardo, et al.
Publicado: (2021)

A Comparative Study of IVIG versus IVIG with IV Methylprednisolone in Guillain–Barre Syndrome
por: Bhattiprolu, Rahi Kiran, et al.
Publicado: (2020)

Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

Neurological update: hereditary neuropathies
por: Kramarz, Caroline, et al.
Publicado: (2022)

Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
por: Zhang, Wei, et al.
Publicado: (2023)

Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis
por: Srkalovic, Gordan, et al.
Publicado: (2005)

Venous thromboembolism in critically ill patients: incidence and risk factors
por: Al-Qahtani, S, et al.
Publicado: (2007)

Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention
por: Zareba, Piotr, et al.
Publicado: (2018)

The Cumulative Incidence and Risk Factors of Recurrent Venous Thromboembolism in the Elderly
por: Aleidan, Fahad A S
Publicado: (2020)

Incident thrombus location and predicting risk of recurrent venous thromboembolism
por: Lidstrom, Sara C., et al.
Publicado: (2022)

Eczematous reaction to IVIG for the treatment of dermatomyositis()()
por: Berk-Krauss, J., et al.
Publicado: (2018)

Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
por: Zhu, Xiao-Lu, et al.
Publicado: (2022)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients
por: Barrett, Aisling, et al.
Publicado: (2021)

Correlation between the Level of Inflammatory Cytokines and Prognosis in Children with IVIG-sensitive Kawasaki Disease and IVIG-resistant Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2022)

Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies
por: Burnor, Elisabeth, et al.
Publicado: (2018)

Plasma neurofilament light chain concentration in the inherited peripheral neuropathies
por: Sandelius, Åsa, et al.
Publicado: (2018)

Metabolites Associated With the Risk of Incident Venous Thromboembolism: A Metabolomic Analysis
por: Jiang, Xia, et al.
Publicado: (2018)

Incidence and Risk Factors of Recurrent Venous Thromboembolism after Pulmonary Embolism
por: Hwang, Hun-Gyu, et al.
Publicado: (2019)

Incidence and risk factors of perioperative venous thromboembolism in patients with cervical cancer
por: Zhao, Hongle, et al.
Publicado: (2022)

Hand grip strength and risk of incident venous thromboembolism: The Tromsø study
por: Leknessund, Oda G. R., et al.
Publicado: (2022)

Independent risk factors for an increased incidence of thromboembolism after lung transplantation
por: Moneke, Isabelle, et al.
Publicado: (2022)

Can compressive thoracic cord lesions cause a pure lower motor neurone syndrome?
por: Kok, Chin Yong, et al.
Publicado: (2019)

IVIG Treatment and Prognosis in Guillain–Barré Syndrome
por: van Doorn, Pieter A., et al.
Publicado: (2010)

IVIG Effects on Erythrocyte Sedimentation Rate in Children
por: Salehzadeh, Farhad, et al.
Publicado: (2014)

Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
por: De Groot, Anne S., et al.
Publicado: (2013)

IVIG regulates the survival of human but not mouse neutrophils
por: Schneider, Christoph, et al.
Publicado: (2017)

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
por: Hooper, John A.
Publicado: (2008)

Unraveling the mechanisms of IVIG immunotherapy in MIS-C
por: Ganigara, Madhusudan, et al.
Publicado: (2021)

Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
por: DeBiasi, Roberta L.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_npmud7443bksvcbeaerj3mieri